Evidence map›Paper›PMID 22301798›Full record

ReviewNature reviews. Drug discovery2012

The secret ally: immunostimulation by anticancer drugs.

Lorenzo Galluzzi, Laura Senovilla, Laurence Zitvogel, Guido Kroemer

2 registry-linked trialsAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Drug discovery, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 397 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
397citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02649829 phase1 / phase2completednot on this mapstarted 2017, after this paper: background citation

First-line Immunotherapy Using Wilms' Tumor Protein 1 (WT1)-Targeted Dendritic Cell Vaccinations for Malignant Pleural Mesothelioma

TypeinterventionalSponsorUniversity Hospital, AntwerpRan2017 to 2025Enrolled28ConditionsMalignant Pleural MesotheliomaArmsdendritic cell vaccination plus chemotherapy
NCT03536780 phase2unknown statusnot on this mapstarted 2018, after this paper: background citation

Phase II Trial of Avelumab in Combination With Gemcitabine in Advanced Leiomyosarcoma as a Second-line Treatment

TypeinterventionalSponsorGachon University Gil Medical CenterRan2018 to 2022Enrolled38ConditionsLeiomyosarcoma MetastaticArmsAvelumab and Gemcitabine
3 · Its place in the literature

Who cites it

397 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

337 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lorenzo GalluzziINSERM U848, Institut Gustave Roussy, Pavillon de Recherche 1, 39 rue Camille Desmoulins, F-94805 Villejuif, France.
Laura Senovilla
Laurence Zitvogel
Guido Kroemer

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It has recently become clear that the tumour microenvironment, and in particular the immune system, has a crucial role in modulating tumour progression and response to therapy. Indicators of an ongoing immune response, such as the composition of the intratumoural immune infiltrate, as well as polymorphisms in genes encoding immune modulators, have been correlated with therapeutic outcome. Moreover, several anticancer agents--including classical chemotherapeutics and targeted compounds--stimulate tumour-specific immune responses either by inducing the immunogenic death of tumour cells or by engaging immune effector mechanisms. Here, we discuss the molecular and cellular circuitries whereby cytotoxic agents can activate the immune system against cancer, and their therapeutic implications.

Indexed as

AnimalsAntigens, NeoplasmAntineoplastic AgentsCancer VaccinesHumansImmunizationNeoplasmsAntigens, NeoplasmAntineoplastic AgentsCancer Vaccines

Identifiers

PMID22301798

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.